BIO-RAD LABORATORIES, INC. acquires DiaMed Holding AG

BIO-RAD LABORATORIES, INC. acquired DiaMed Holding AG for approximately 477 million Swiss francs in cash for ~77.7% of shares (with a subsequent tender offer for the remaining ~12.7%), a transaction completed in October 2007, structured as all cash (share purchase agreement plus follow-on tender offer).

DiaMed Holding AG operates in Clinical Diagnostics, is based in Switzerland (sales to hospitals, clinical laboratories and blood banks in more than 100 countries), had revenue of about approximately US $200 million annual sales. DiaMed develops, manufactures and markets a complete line of reagents and instruments used in blood typing and screening. Founded in 1977 and based in Switzerland, DiaMed had annual sales of approximately US $200 million to hospitals, clinical laboratories, and blood banks in more than 100 countries, with nearly 800 employees.

DiaMed has an outstanding reputation for quality products and customer care and we believe this portfolio of products will fit in well with Bio-Rad's existing diagnostics business.

Complete blood typing and screening product line with a strong global reputation, complementing Bio-Rad's diagnostics business. Expands Bio-Rad's clinical diagnostics portfolio into blood typing and screening. Clinical Diagnostics segment

Advisory firms were not disclosed for this transaction.